Pregabalin - Nevakar
Alternative Names: NVK-009; NVK009-0001Latest Information Update: 31 Dec 2021
At a glance
- Originator Nevakar
- Class Acetanilides; Aminobutyric acids; Aminophenols; Analgesics; Antiepileptic drugs; Anxiolytics; Gabapentinoids; Neuroprotectants; Non-opioid analgesics; Small molecules
- Mechanism of Action CACNA2D1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Dental pain; Postoperative pain
Most Recent Events
- 23 Mar 2021 Phase-II development is ongoing in USA (Parenteral) (Nevakar pipeline, March 2021)
- 28 Jul 2020 Phase-II clinical trials in Postoperative pain (In volunteers, Combination therapy) in USA (IV) (NCT04495283)
- 22 Jul 2020 Nevakar completes the phase I trial in Healthy volunteers in USA (IV) (NCT04265456)